The immune microenvironment and progression of immunotherapy and combination therapeutic strategies for hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) accounts for 75%-85% of all primary liver cancers and is the leading cause of cancer-related deaths. China accounts for almost half of the global incidence and deaths of HCC. The poor response of chemotherapeutics and targeted drugs may be due to the drug resistance, heterogeneity of HCC, severe chronic liver damage and cirrhosis. Restoration of the liver microenvironment changes caused by chronic injury is crucial. Immunotherapy recently seems to show promise for the treatment of HCC induced by inflammatory injury. However, the unique liver immune system and resident immune tolerance state also pose a challenge for HCC immunotherapy. Different combinations of strategies have been developed for enhancement of HCC treatment. Here, we will discuss the immune microenvironment and progression of immunotherapy and combination therapeutic strategies for HCC.

Keywords

Immune microenvironment / immunotherapy / immune checkpoint inhibitors / Chimeric antigen receptor T / hepatocellular carcinoma

References

[1] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries..CA Cancer J Clin2018;68:394-424

[2] Liu X.Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges..Oncologist2019;24:S3-10 PMCID:PMC6394775

[3] Montella L,Addeo R.Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?.World J Gastroenterol2016;22:6114-26 PMCID:PMC4945973

[4] Kudo M.A new era of systemic therapy for hepatocellular carcinoma with Regorafenib and Lenvatinib..Liver Cancer2017;6:177-84 PMCID:PMC5473064

[5] Wörns MA.HCC therapies--lessons learned..Nat Rev Gastroenterol Hepatol2014;11:447-52

[6] Hernandez-Gea V,Friedman SL.Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma..Gastroenterology2013;144:512-27 PMCID:PMC3578068

[7] Karin M.Nuclear factor-kappaB in cancer development and progression..Nature2006;441:431-6

[8] Horst AK,Diehl L.Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells..Cell Mol Immunol2016;13:277-92

[9] Buonaguro L,Cavalluzzo B,Tagliamonte M.Immunotherapy in hepatocellular carcinoma..Ann Hepatol2019;18:291-7

[10] Jenne CN.Immune surveillance by the liver..Nat Immunol2013;14:996-1006

[11] Racanelli V.The liver as an immunological organ..Hepatology2006;43:S54-62

[12] Shetty S,Adams DH.Liver sinusoidal endothelial cells - gatekeepers of hepatic immunity..Nat Rev Gastroenterol Hepatol2018;15:555-67

[13] Carambia A,Bruns OT.Inhibition of inflammatory CD4 T cell activity by murine liver sinusoidal endothelial cells..J Hepatol2013;58:112-8

[14] Diehl L,Grochtmann R,Chen L.Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance..Hepatology2008;47:296-305

[15] Schildberg FA,Schumak B,Limmer A.Liver sinusoidal endothelial cells veto CD8 T cell activation by antigen-presenting dendritic cells..Eur J Immunol2008;38:957-67

[16] Dixon LJ,Tang H,Nagy LE.Terjung R.Kupffer cells in the liver..Comprehensive physiology.2013;HobokenJohn Wiley & Sons, Inc.

[17] Thomson AW.Antigen-presenting cell function in the tolerogenic liver environment..Nat Rev Immunol2010;10:753-66

[18] You Q,Kedl RM.Mechanism of T cell tolerance induction by murine hepatic Kupffer cells..Hepatology2008;48:978-90 PMCID:PMC2600585

[19] Ormandy LA,Wedemeyer H,Greten TF.Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma..Cancer Res2005;65:2457-64

[20] Dou L,Chen YF,Chen XP.Hepatic dendritic cells, the tolerogenic liver environment, and liver disease..Semin Liver Dis2018;38:170-80

[21] Severi T,Verslype C.Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets..Acta Pharmacol Sin2010;31:1409-20 PMCID:PMC4003336

[22] Qin LX.Inflammatory immune responses in tumor microenvironment and metastasis of hepatocellular carcinoma..Cancer Microenviron2012;5:203-9 PMCID:PMC3460054

[23] Cancer Genome Atlas Research Network. Cancer Genome Atlas Research NetworkComprehensive and integrative genomic characterization of hepatocellular carcinoma..Cell2017;169:1327-41.e23 PMCID:PMC5680778

[24] Sia D,Martinez-Quetglas I.Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features..Gastroenterology2017;153:812-26

[25] Behboudi S,Williams R.Cell-mediated immune responses to alpha-fetoprotein and other antigens in hepatocellular carcinoma..Liver Int2010;30:521-6

[26] Fu J,Liu Z.Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients..Gastroenterology2007;132:2328-39

[27] Yang YM,Seki E.Inflammation and liver cancer: molecular mechanisms and therapeutic targets..Semin Liver Dis2019;39:26-42 PMCID:PMC6616367

[28] Liu CY,Chen PJ.Treatment of liver cancer..Cold Spring Harb Perspect Med2015;5:a021535 PMCID:PMC4561392

[29] Jadid FZ,Alj HS.Control of progression towards liver fibrosis and hepatocellular carcinoma by SOCS3 polymorphisms in chronic HCV-infected patients..Infect Genet Evol2018;66:1-8

[30] Kudo M.Immuno-oncology in hepatocellular carcinoma: 2017 Update..Oncology.2017;93 Suppl 1:147-59

[31] Chuang W,Chang W.Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor invasion..Cancer1990;65:926-30

[32] Wu Y,Pan WD.Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions..Hepatology2013;57:1107-16

[33] Abril-Rodriguez G.SnapShot: immune checkpoint inhibitors..Cancer Cell2017;31:848.e1

[34] Chen G,Zhang W.Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response..Nature2018;560:382-6 PMCID:PMC6095740

[35] Robert C,Brady B.Nivolumab in previously untreated melanoma without BRAF mutation..N Engl J Med2015;372:320-30

[36] El-khoueiry AB,Yau T.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial..Lancet2017;389:2492-502 PMCID:PMC7539326

[37] Zhu AX,Edeline J.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial..Lancet Oncol2018;19:940-52

[38] Kudo M.Molecular targeted therapy for hepatocellular carcinoma: where are we now?.Liver Cancer2015;4:I-VII PMCID:PMC4716409

[39] Zhang B.Personalized clinical trials in hepatocellular carcinoma based on biomarker selection..Liver Cancer2016;5:221-32 PMCID:PMC4960351

[40] Bruix J,Merle P.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial..Lancet2017;389:56-66

[41] Yoo C,Kim YJ.Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma..Invest New Drugs2019;37:567-72

[42] Yoo C,Kim SY.Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours..Br J Cancer2019;121:819-26 PMCID:PMC6888806

[43] Titano J,Kim E.Transarterial chemoembolization and radioembolization across barcelona clinic liver cancer stages..Semin Intervent Radiol2017;34:109-15 PMCID:PMC5453775

[44] Bolondi L,Dufour JF.Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions..Semin Liver Dis2012;32:348-59

[45] El-Khoueiry AB,Yau T.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial..Lancet2017;389:2492-502 PMCID:PMC7539326

[46] Yau T,Kim TY.Nivolumab in advanced hepatocellular carcinoma: sorafenib-experienced Asian cohort analysis..J Hepatol2019;71:543-52

[47] Lichty BD,Stojdl DF.Going viral with cancer immunotherapy..Nat Rev Cancer2014;14:559-67

[48] Guo ZS,Bartlett DL.Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses..Biochim Biophys Acta2008;1785:217-31 PMCID:PMC2888475

[49] Akira S,Kaisho T.Toll-like receptors: critical proteins linking innate and acquired immunity..Nat Immunol2001;2:675-80

[50] Kato H,Sato S.Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses..Nature2006;441:101-5

[51] Kaufman HL,Zloza A.Oncolytic viruses: a new class of immunotherapy drugs..Nat Rev Drug Discov2015;14:642-62 PMCID:PMC7097180

[52] Yoo SY,Woo HY.Oncolytic virus-based immunotherapies for hepatocellular carcinoma..Mediators Inflamm2017;2017:5198798

[53] Kanerva A,Diaconu I.Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus..Clin Cancer Res2013;19:2734-44

[54] Kirn DH.Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer..Nat Rev Cancer2009;9:64-71

[55] Abdullahi S,Behrend SJ.A novel chimeric oncolytic virus vector for improved safety and efficacy as a platform for the treatment of hepatocellular carcinoma..J Virol2018;92:e01386-18 PMCID:PMC6232488

[56] Zhang H,Lin Y.Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma..Sci Transl Med2017;9:eaam7996

[57] Luo Y,Ren W.Intravenous injections of a rationally selected oncolytic herpes virus as a potent virotherapy for hepatocellular carcinoma..Mol Ther Oncolytics2019;15:153-65

[58] Chen A,Meng G.Oncolytic measles virus enhances antitumour responses of adoptive CD8(+)NKG2D(+) cells in hepatocellular carcinoma treatment..Sci Rep2017;7:5170 PMCID:PMC5507973

[59] Xie W,Zhang K.Adenovirus armed with VGLL4 selectively kills hepatocellular carcinoma with G2/M phase arrest and apoptosis promotion..Biochem Biophys Res Commun2018;503:2758-63

[60] Nakatake R,Nakamura Y.Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice..Cancer Sci2018;109:600-10 PMCID:PMC5834814

[61] El-Shemi AG,Oh E.Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: first evidence in preclinical hepatocellular carcinoma..Gene Ther2018;25:54-65 PMCID:PMC5817393

[62] Zhang J,Li Q.A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models..Biochem Biophys Res Commun2017;491:469-77

[63] Lv SQ,Liu PY.11R-P53 and GM-CSF expressing oncolytic adenovirus target cancer stem cells with enhanced synergistic activity..J Cancer2017;8:199-206

[64] El-Shemi AG,Na Y.Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model..J Exp Clin Cancer Res2016;35:74 PMCID:PMC4859966

[65] Ruf B,Venturelli S.Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma..Mol Ther Oncolytics2015;2:15019 PMCID:PMC4782956

[66] Ady JW,Mojica K,Love D.Oncolytic gene therapy with recombinant vaccinia strain GLV-2b372 efficiently kills hepatocellular carcinoma..Surgery2015;158:331-8 PMCID:PMC4819004

[67] Ady JW,Mojica K.Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently..Surgery2014;156:263-9 PMCID:PMC4216725

[68] Lin WH,Yang WJ.Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice..Int J Cancer2013;132:1451-62

[69] Wang J,Zeng W.Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta..Cancer Cell Int2014;14:83 PMCID:PMC4213511

[70] Fu X,Tao L.Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells..Mol Ther2012;20:339-46 PMCID:PMC3277243

[71] Gentschev I,Adelfinger M.Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68..PLoS One2011;6:e22069

[72] Jin H,Yang J.Use of microRNA Let-7 to control the replication specificity of oncolytic adenovirus in hepatocellular carcinoma cells..PLoS One2011;6:e21307 PMCID:PMC3140979

[73] Lee JH,Lee YK.Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model..Cancer Gene Ther2010;17:73-9 PMCID:PMC2834359

[74] Wein LM,Kirn DH.Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery..Cancer Res2003;63:1317-24

[75] Thorne SH,O’Gorman WE.Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963..J Clin Invest2007;117:3350-8 PMCID:PMC2040321

[76] Kim JH,Park BH.Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF..Mol Ther2006;14:361-70

[77] Parato KA,Le Boeuf F.The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers..Mol Ther2012;20:749-58 PMCID:PMC3321594

[78] Park B,Liu T.Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial..Lancet Oncology2008;9:533-42

[79] Heo J,Ruo L.Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer..Nat Med2013;19:329-36 PMCID:PMC4268543

[80] Moehler M,Lee HC.Vaccinia-based oncolytic immunotherapy pexastimogene devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)..Oncoimmunology2019;8:1615817 PMCID:PMC6682346

[81] Heo J,Ruo L.Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer..Nat Med2013;19:329-36 PMCID:PMC4268543

[82] Moehler M,Lee HC.Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)..Oncoimmunology2019;8:1615817 PMCID:PMC6682346

[83] Park BH,Liu TC.Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial..Lancet Oncol2008;9:533-42

[84] Rizell M,Andersson M.Phase 1 trial with the cell-based immune primer ilixadencel, alone, and combined with sorafenib, in advanced hepatocellular carcinoma..Front Oncol2019;9:19 PMCID:PMC6348253

[85] Ning N,Zheng F.Cancer stem cell vaccination confers significant antitumor immunity..Cancer Res2012;7:1853-64 PMCID:PMC3320735

[86] Johnston MP.Immunotherapy for hepatocellular carcinoma: current and future..World J Gastroenterol2019;25:2977-89 PMCID:PMC6603808

[87] Gustafsson K,Bergqvist L,Andersson B.Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine..Cancer Res2008;68:5965-71

[88] Shang N,Shangguan J.Dendritic cells based immunotherapy..Am J Cancer Res2017;7:2091-102 PMCID:PMC5665855

[89] Rizell M,Andersson M,Karlsson-Parra A.Phase 1 trial with the cell-based immune primer ilixadencel, alone, and combined with sorafenib, in advanced hepatocellular carcinoma..Front Oncol2019;9:19 PMCID:PMC6348253

[90] Jena B,Cooper LJ.Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor..Blood2010;116:1035-44 PMCID:PMC2938125

[91] Jiang Z,Chen S.Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma..Front Immunol2016;7:690 PMCID:PMC5225101

[92] Wang Y,Wu Z.CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial..Oncoimmunology2018;7:e1440169 PMCID:PMC5993480

[93] Li D,Zhang YF.Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice..Gastroenterology2020;158:2250-65.e20 PMCID:PMC7282931

[94] Liu X,Yi H.Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release..Ther Adv Med Oncol2020;12:1758835920910347 PMCID:PMC7065297

[95] Sun B,Dai H.Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells..Cancer Immunol Res2019;7:1813-23

[96] Zhang RY,Liu ZK.Doxycycline inducible chimeric antigen receptor T cells targeting CD147 for hepatocellular carcinoma therapy..Front Cell Dev Biol2019;7:233 PMCID:PMC6798074

[97] Morgan RA,Davis JL.Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma..Hum Gene Ther2012;23:1043-53 PMCID:PMC3472555

[98] Finney HM,Lawson AD.Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain..J Immunol2004;172:104-13

[99] Yau T,Kim TY.Efficacy and safety of Nivolumab plus Ipilimumab in patients with advanced hepatocellular carcinoma previously treated with Sorafenib: the CheckMate 040 randomized clinical trial..JAMA Oncol2020;e204564: PMCID:PMC7530824

[100] Finn RS,Ikeda M.Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma..N Engl J Med2020;382:1894-905